The US FDA will consider several factors when considering whether to grant a waiver of the single shared system Risk Evaluation and Mitigation Strategy requirement for a generic drug sponsor, including the impact a separate system could have on generic entry.
Draft guidance issued May 31 also outlines what ANDA sponsors should include in a waiver request, but FDA made clear...



